Clinical trial
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for…
NCT00146562 · Harold J. Burstein, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00146562 |
|---|---|
| Title | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer |
| Official title | A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer |
| Lead sponsor | Harold J. Burstein, MD, PhD, Other |
| Collaborators | Dana-Farber Cancer Institute Massachusetts General Hospital Beth Israel Deaconess Medical Center Lowell General Hospital Brigham and Women's Hospital North Shore Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide |
| Enrollment | 135 |
| Start date | Jul 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Aug 2, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: